1. Home
  2. GKOS vs MAIN Comparison

GKOS vs MAIN Comparison

Compare GKOS & MAIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Glaukos Corporation

GKOS

Glaukos Corporation

HOLD

Current Price

$113.41

Market Cap

6.4B

Sector

Health Care

ML Signal

HOLD

Logo Main Street Capital Corporation

MAIN

Main Street Capital Corporation

HOLD

Current Price

$61.27

Market Cap

5.4B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
GKOS
MAIN
Founded
1998
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Finance/Investors Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
6.4B
5.4B
IPO Year
2015
2007

Fundamental Metrics

Financial Performance
Metric
GKOS
MAIN
Price
$113.41
$61.27
Analyst Decision
Strong Buy
Hold
Analyst Count
14
7
Target Price
$127.71
$61.57
AVG Volume (30 Days)
641.9K
583.0K
Earning Date
02-19-2026
02-26-2026
Dividend Yield
N/A
6.85%
EPS Growth
N/A
9.38
EPS
N/A
6.03
Revenue
$469,820,000.00
$561,290,000.00
Revenue This Year
$31.15
$5.53
Revenue Next Year
$24.15
$2.24
P/E Ratio
N/A
$10.32
Revenue Growth
30.38
5.92
52 Week Low
$73.16
$47.00
52 Week High
$163.71
$67.77

Technical Indicators

Market Signals
Indicator
GKOS
MAIN
Relative Strength Index (RSI) 58.14 53.55
Support Level $109.07 $60.39
Resistance Level $115.00 $62.63
Average True Range (ATR) 2.76 1.14
MACD -0.95 0.05
Stochastic Oscillator 44.01 62.25

Price Performance

Historical Comparison
GKOS
MAIN

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

About MAIN Main Street Capital Corporation

Main Street Capital Corp is an investment firm engaged in providing customized debt and equity financing to lower middle market companies and debt capital to middle market companies. The investment portfolio of the company is typically made to support management buyouts, recapitalizations, growth financings, refinancing, and acquisitions of companies that operate in diverse industry sectors. The group invests in secured debt investments, equity investments, warrants, and other securities of the lower middle market and middle market companies based in the United States. Business functioned through the U.S. region and it derives the majority of its income from the source of fees, commission, and interest.

Share on Social Networks: